Literature DB >> 3410169

Long-term omeprazole treatment in man: effects on gastric endocrine cell populations.

R Lamberts1, W Creutzfeldt, F Stöckmann, U Jacubaschke, S Maas, G Brunner.   

Abstract

36 patients with chronic gastric or oesophageal peptic ulceration (including 6 with antrectomy), resistant to high-dose ranitidine treatment for at least 3 months, were successfully treated with 40-60 mg of omeprazole daily for periods between 1 and 2 years. Fasting serum gastrin levels were monitored at regular intervals during therapy and multiple gastric mucosal biopsies were taken during gastroscopy every 3-6 months. Gastrin levels increased significantly during the first 6 months of therapy from a medium level of 81.5 to 206 pg/ml, a slight decrease was seen thereafter. In 10 patients investigated before the start of the treatment and after 1 and 2 years, the volume density of argyrophilic cells in the oxyntic mucosa increased from 0.43 +/- 0.08 to 0.91 +/- 0.14% during the first year; this change was statistically significant. No further increase was observed thereafter. No such difference could be demonstrated between a larger group of 18 patients investigated before and after 1 year of treatment with omeprazole (0.806 +/- 0.1 vs. 0.93 +/- 0.08%) and between a larger group of 22 untreated patients and 17 patients treated for 17-24 months with omeprazole (0.73 +/- 0.1 vs. 0.86 +/- 0.09%). The volume density of argyrophilic cells found in 8 patients with gastrinoma amounted to 1.37 +/- 0.22%. No clusters of endocrine cells were found in omeprazole-treated patients. The D cell volume density in the antral mucosa decreased significantly during the first months of treatment, but steadily increased thereafter to reach pretreatment values after 17 months. There was no change in G cell volume density under therapy. No changes in gastrin levels or oxyntic argyrophilic cells were observed in the antrectomized patients. It is concluded that the hyperplasia of argyrophilic cells observed in some patients during long-term omeprazole treatment is mediated by hypergastrinaemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410169     DOI: 10.1159/000199615

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  39 in total

1.  The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.

Authors:  T D Barrett; G Lagaud; P Wagaman; J M Freedman; W Yan; L Andries; M C Rizzolio; M F Morton; N P Shankley
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

3.  Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

Authors:  L C Baak; J B Jansen; I Biemond; C B Lamers
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

Authors:  T K Daneshmend; A G Stein; N K Bhaskar; C J Hawkey
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

Review 5.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

Review 6.  Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies.

Authors:  Jeong Soo Ahn; Chun-Sick Eom; Christie Y Jeon; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

7.  Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease.

Authors:  M Coupe; H Rees; C J Springer; A E Bishop; J A Morris; J M Polak; J Calam
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

8.  Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.

Authors:  G E Feurle
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

9.  Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man.

Authors:  J L Meijer; J B Jansen; L F Crobach; I Biemond; C B Lamers
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

10.  Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.

Authors:  A H Poulsen; S Christensen; J K McLaughlin; R W Thomsen; H T Sørensen; J H Olsen; S Friis
Journal:  Br J Cancer       Date:  2009-04-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.